Tag: NASDAQ:LJPC

FB Nasdaq FB Facebook
Finance

Biotech Losers: Agenus Inc (NASDAQ:AGEN), La Jolla Pharmaceutical Company (NASDAQ:LJPC), Durata Therapeutics (NASDAQ:DRTX), Galmed Pharmaceuticals (NASDAQ:GLMD)

Shares of Agenus Inc (NASDAQ:AGEN) , a biopharmaceutical company focused on developing novel immunotherapies to treat cancer and a number of other unmet diseases, tumbled by as much as 22% after partner GlaxoSmithKline (NYSE: GSK ) announced that its phase 3 MAGE-A3 cancer immunotherapeutic trial in non-small cell lung cancer (NSCLC) patients didn’t meet its first or second coprimary endpoint. Agenus Inc (NASDAQ:AGEN) stock performance … Continue reading Biotech Losers: Agenus Inc (NASDAQ:AGEN), La Jolla Pharmaceutical Company (NASDAQ:LJPC), Durata Therapeutics (NASDAQ:DRTX), Galmed Pharmaceuticals (NASDAQ:GLMD)

Kevin Long
BioTech

Biotech Losers: Discovery Laboratories (NASDAQ:DSCO), CEL-SCI Corporation (NYSEMKT:CVM), NewLink Genetics (NASDAQ:NLNK), La Jolla Pharmaceutical (NASDAQ:LJPC)

Discovery Laboratories, Inc. (NASDAQ:DSCO) has been upgraded by TheStreet Ratings from sell to hold. Discovery Laboratories, Inc. (NASDAQ:DSCO) stock performance was -6.01% in last session and finished the day at $2.19. Traded volume was 1,245,476 million shares in the last session and the average volume of the stock remained 589.46 million shares. The beta of the stock remained 1.35. Discovery Laboratories, Inc. (NASDAQ:DSCO) insider ownership … Continue reading Biotech Losers: Discovery Laboratories (NASDAQ:DSCO), CEL-SCI Corporation (NYSEMKT:CVM), NewLink Genetics (NASDAQ:NLNK), La Jolla Pharmaceutical (NASDAQ:LJPC)

Mark Doerr
BioTech

Biotech Unusual Volume Stocks: Arca Biopharma (NASDAQ:ABIO), Biota Pharmaceuticals (NASDAQ:BOTA), Lpath (NASDAQ:LPTN), La Jolla Pharmaceutical (NASDAQ:LJPC)

Arca Biopharma Inc (NASDAQ:ABIO) focuses on developing genetically targeted therapies for cardiovascular disease. Its lead product candidate, Gencaro, is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the prevention of atrial fibrillation in patients with heart failure and reduced left ventricular ejection fraction. Arca Biopharma Inc (NASDAQ:ABIO) stock performance was 11.34% in last session and finished the day at $2.16. Traded volume … Continue reading Biotech Unusual Volume Stocks: Arca Biopharma (NASDAQ:ABIO), Biota Pharmaceuticals (NASDAQ:BOTA), Lpath (NASDAQ:LPTN), La Jolla Pharmaceutical (NASDAQ:LJPC)

Mark DeFrance
BioTech

Biotech Unusual Volume: Northwest Biotherapeutics (NASDAQ:NWBO), La Jolla Pharmaceutical Company (NASDAQ:LJPC), OXiGENE (NASDAQ:OXGN), Tengion (OTCMKTS:TNGN)

Northwest Biotherapeutics Inc (NASDAQ:NWBO) a biotechnology company developing DCVax personalized immune therapies for solid tumour cancers, has received approval from the Paul Ehrlich Institute (PEI- the FDA of Germany) of a “Hospital Exemption” early access programme under Section 4b of the German Drug Law. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) stock performance was 16.93% in last session and finished the day at $9.18. Traded volume was 8,391,894 … Continue reading Biotech Unusual Volume: Northwest Biotherapeutics (NASDAQ:NWBO), La Jolla Pharmaceutical Company (NASDAQ:LJPC), OXiGENE (NASDAQ:OXGN), Tengion (OTCMKTS:TNGN)

Mark DeFrance
BioTech

Biotech Unusual Volume: Agios Pharmaceuticals (NASDAQ:AGIO), OHR (NASDAQ:OHRP), La Jolla (NASDAQ:LJPC), Aastrom Biosciences (NASDAQ:ASTM)

Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a research report issued to clients and investors on Monday, Analyst Ratings News reports. Agios Pharmaceuticals Inc (NASDAQ:AGIO) stock performance was 2.84% in last session and finished the day at $46.74. Traded volume was 983,271 million shares in the last session and the average volume of the stock remained … Continue reading Biotech Unusual Volume: Agios Pharmaceuticals (NASDAQ:AGIO), OHR (NASDAQ:OHRP), La Jolla (NASDAQ:LJPC), Aastrom Biosciences (NASDAQ:ASTM)

Richard Atkins